Showing results (631-640 of 727) with videos related to

Sort By:
Pageof 73
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerJustin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
The Science of the Total Environment|February 19, 2024
Equipping for risk: Lessons learnt from the UK shale-gas experience on assessing environmental risks for the future geoenergy use of the deep subsurfaceP L Smedley, G Allen, B J Baptie, et al.
The British Journal of Radiology|June 3, 2026
Stereotactic Radiosurgery (SRS) for Small Cell Lung Cancer (SCLC) brain metastases: a real-world UK tertiary centre experienceD J McMahon, A John, T Ketpueak, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 5, 2023
NgR1 binding to reovirus reveals an unusual bivalent interaction and a new viral attachment proteinDanica M Sutherland, Michael Strebl, Melanie Koehler, et al.
JAMA Oncology|October 24, 2024
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical TrialKartik Sehgal, Theodora Pappa, Kee-Young Shin, et al.
Science Immunology|June 21, 2020
Rate of replenishment and microenvironment contribute to the sexually dimorphic phenotype and function of peritoneal macrophagesC C Bain, D A Gibson, N J Steers, et al.
Cancer Discovery|March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerJim Sang, Jaime Acquaviva, Julie C Friedland, et al.
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung CancerCaroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
Pageof 73